At present, there is an increased focus on the analysis in cfDNA of cancer-related genomic alterations, such as mutations in KRAS, TP53, PIK3CA, or p16 genes, by using new highly sensitive technologies such as digital droplet PCR (ddPCR), BEAMing (beads, emulsion, amplification and magnetics) or next-generation sequencing (NGS) approaches (21). The gene discussed is KRAS; the disease is cancer.